SPOTLIGHT -
Washington-Two urology organizations have made good on their promise to fight the Stark II regulations with legal action.
Proteogenomic analysis identifies biomarkers for non-ccRCC subtypes
"Until now, no single center has had enough samples of the quality needed for comprehensive multi-omics profiling, as we’ve carried out in this study,” says Saravana Mohan M. Dhanasekaran, PhD.
Health policy in urology: 2024 AUA Advocacy Summit recap
In this episode of Speaking of Urology®, Eugene Rhee, MD, MBA, and Logan Galansky, MD, discuss key topics in health policy and recap the AUA's recent Annual Urology Advocacy Summit.
FDA accepts sNDA for vibegron for OAB symptoms in pharmacologically treated BPH
The Prescription Drug User Fee Act target action date is set for quarter 3 of this year.
Dr. Murphy on increasing diversity in cancer clinical trials
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Combo of burst wave lithotripsy and ultrasonic propulsion feasible for kidney stones
Combination treatment with burst wave lithotripsy and ultrasonic propulsion for small, asymptomatic renal stones is feasible.
Dosing begins in study of PSMA-targeted therapy in mCRPC
The phase 2/3 AlphaBreak trial is evaluating the safety and efficacy of FPI-2265 in patients with mCRPC who have been previously treated with 177Lu-PSMA radiotherapy.